Drug intelligence / Profile preview

SND4

Development stage: Preclinical
Lead developer: SyneuRx International
Modality: Small Molecules

Overview

SND4 is a preclinical-stage small molecule D-amino acid oxidase (DAAO) inhibitor developed by SyneuRx for the treatment of adult schizophrenia. DAAO is an enzyme responsible for the degradation of D-amino acids, including D-serine, which acts as a crucial co-agonist at the N-methyl-D-aspartate (NMDA) receptor. By inhibiting DAAO, SND4 aims to increase the levels of D-serine in the brain, thereby enhancing NMDA receptor function and addressing the glutamatergic hypofunction associated with the pathophysiology of schizophrenia. The drug is currently in the preclinical phase of development.

Targets

DAO (D-amino-acid oxidase)

Beyond the preview

Go deeper on SND4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SND4.

Explore the full profile